Phase II Trial of Nivolumab and HPV-16 Vaccination in Patients With HPV-16-Positive Incurable Solid Tumors
Phase of Trial: Phase II
Latest Information Update: 12 Sep 2017
At a glance
- Drugs ISA 101 (Primary) ; Nivolumab
- Indications Solid tumours
- Focus Therapeutic Use
- 12 Sep 2017 Primary endpoint has been met. (Overall Response Rate (ORR)), according to results presented at the 42nd European Society for Medical Oncology Congress.
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress.
- 04 Sep 2017 Status changed from active, no longer recruiting to completed, according to an ISA Pharmaceuticals media release.